share_log

Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand

Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand

諾和諾德將在中國高需求情況下限制維果美首次銷售
Benzinga ·  06/27 12:13

Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply.

丹麥藥企諾和諾德(Novo Nordisk A/S)計劃在中國限制肥胖症治療藥物Wegovy的初步銷售,面對全球供應保障與市場需求之間的挑戰。

China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.

我國國家衛生健康委員會的一項調查發現,超過14億人口中超過一半的人超重或肥胖。

Also Read: Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows.

還閱讀:諾和諾德的老一代減重藥Saxenda與骨密度減少有關的研究結果。

Maziar Mike Doustdar, Novo Nordisk's chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere.

諾和諾德的國際業務總監Maziar Mike Doustdar表示,該公司計劃很快在中國推出Wegovy,優先考慮連續供應而不影響其他地區的可用性。

China's health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk's diabetes drug, Ozempic, has been used off-label to shed weight.

中國的衛生主管部門最近批准了Wegovy,爲市場提供了一種新的減重選擇,而諾和諾德的糖尿病藥物Ozempic已被用於減肥的非標籤使用。

As urbanization drives obesity rates, China's market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030, Bloomberg notes, citing HSBC analysis.

隨着城市化推動肥胖率不斷攀升,根據匯豐銀行分析,中國對GLP-1類藥物(如Wegovy)的市場規模到2030年可能會達到400億元人民幣(55億美元)。

However, Novo Nordisk's patent on semaglutide, Wegovy's active ingredient, expires in 2026, with Hangzhou Jiuyuan Gene Engineering Co. and Livzon Pharmaceutical Group Inc. already seeking to produce generic versions.

然而,Wegovy的活性成分Semaglutide的專利將在2026年到期,杭州九元基因工程有限公司和立博藥業集團已經尋求生產仿製藥。

Eli Lilly And Co (NYSE:LLY) is also a key competitor, with its obesity drug under review in China. Lilly and Innovent Biologics Inc. are also developing a local weight-loss drug that is expected to launch next year.

禮來公司(Eli Lilly And Co)也是一家重要的競爭者,其肥胖症藥物正在中國審批中。禮來公司和信達生物股份有限公司還在開發本地減肥藥物,預計明年推出。

Bloomberg report adds that Novo Nordisk has struggled to meet global demand for Wegovy and Ozempic, but it continues to manufacture semaglutide in Denmark and North Carolina and is planning final production stages in China.

彭博社的報道稱,諾和諾德一直在努力滿足Wegovy和Ozempic的全球需求,但仍在丹麥和北卡羅萊納州生產Semaglutide,並計劃在中國進行最終生產階段。

A 4 billion yuan factory expansion in Tianjin was announced in March.

3月份宣佈在天津進行40億元的工廠擴建。

While China's national health insurance covers Ozempic for diabetes, Wegovy is unlikely to receive similar reimbursement.

雖然我國的國家醫保覆蓋了糖尿病患者的Ozempic,但Wegovy不太可能獲得類似的報銷。

As a result, Wegovy will likely target those able to pay out-of-pocket, allowing Novo Nordisk to set prices independently.

因此,Wegovy可能會瞄準那些能夠自己支付的人,讓諾和諾德能夠自主定價。

Currently, Ozempic is available on major Chinese platforms like JD.com Inc (NASDAQ:JD) and Alibaba Group Holding Ltd.'s (NYSE:BABA) Tmall.

目前,Ozempic可以在中國主要平台,如京東和阿里巴巴旗下的天貓上購買。

Price Action: NVO shares are down 0.10% at $143.52 at last check Thursday.

據最新資料,紐交所上諾和諾德的股票NVO,週四收盤價爲143.52美元,下跌0.10%。

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

免責聲明:本文部分內容使用了Benzinga Neuro的幫助。此內容是通過AI工具部分製作的,並由Benzinga編輯進行了審查和發佈。

Photo by Tobias Arhelger via Shutterstock

圖片由shutterstock提供

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論